Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK).
Farmer, L.J., Bemis, G., Britt, S.D., Cochran, J., Connors, M., Harrington, E.M., Hoock, T., Markland, W., Nanthakumar, S., Taslimi, P., Ter Haar, E., Wang, J., Zhaveri, D., Salituro, F.G.(2008) Bioorg Med Chem Lett 18: 6231-6235
- PubMed: 18938080
- DOI: https://doi.org/10.1016/j.bmcl.2008.09.106
- Primary Citation of Related Structures:
3EMG - PubMed Abstract:
A series of SYK inhibitors based on the phenylamino pyrimidine thiazole lead 4 were prepared and evaluated for biological activity. Lead optimization provided compounds with nanomolar K(i)'s against SYK and potent inhibition in mast cell degranulation assays.
Organizational Affiliation:
Department of Medicinal Chemistry, Vertex Pharmaceuticals, Inc., 130 Waverly Street, Cambridge, MA 02139, USA. luc_farmer@vrtx.com